Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Kidney Cancer
Obesity Tied to Increased Mortality Overall in Patients With Cancer, But Not RCC
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity
Fotivda Now Available for Renal Cell Carcinoma
Fotivda is an oral vascular endothelial growth factor tyrosine kinase inhibitor.
FDA-Approved VEGFR Tyrosine Kinase Inhibitors Ranked by Cardiotoxic Potential
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
Belzutifan Gets Priority Review for Von Hippel-Lindau Disease-Associated RCC
Belzutifan is a potent and selective inhibitor of HIF-2α.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC).
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
-
Loading...
-
Loading...
Next post in Genitourinary Cancers Symposium
